UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as | NYSE: DGX S&P 500 Component |
| Industry | Health care |
| Founded | New York City, United States (1967) |
| Founder | Paul Brown |
| Headquarters | Madison, New Jersey, United States |
|
Area served
|
United States, Brazil, Mexico, United Kingdom, India |
|
Key people
|
Steve Rusckowski (CEO) |
| Revenue |  US$7.5 Billion (2015) |
|
Operating income
|
US$1.4 Billion (2015) |
|
Net income
|
US$0.7 Billion(2015) |
| Total assets | US$10.0 Billion(2015) |
| Total equity | US$4.7 Billion (2015) |
|
Number of employees
|
44,000 (2015) |
| Website | questdiagnostics |
Quest Diagnostics Incorporated is a Fortune 500 American company providing clinical laboratory services with headquarters in Secaucus, New Jersey. Founded in 1967 as Metropolitan Pathology Laboratory, Inc., it became an independent corporation with the Quest name on December 31, 1996. In addition to the United States, Quest Diagnostics also runs operations in United Kingdom, Mexico, Brazil, Puerto Rico and a laboratory in India and also has collaborative agreements internationally with various hospitals and clinics. The company has approximately 44,000 employees, generates more than $7 billion in revenue and offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease and neurological disorders.
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical lab for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state’s Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-10-20 | 2.36 | 2.36 |
| Q2 2022 | 2022-07-21 | 2.36 | 2.36 |
| Q1 2022 | 2022-04-21 | 3.22 | 3.22 |
| Q4 2021 | 2022-02-03 | 3.33 | 3.33 |
| Q3 2021 | 2021-10-21 | 3.96 | 3.96 |
| Q2 2021 | 2021-07-22 | 3.18 | 3.18 |
| Q1 2021 | 2021-04-22 | 3.76 | 3.76 |
| Q4 2020 | 2021-02-04 | 4.48 | 4.48 |
| Q3 2020 | 2020-10-22 | 4.31 | 4.31 |
| Q2 2020 | 2020-07-23 | 1.42 | 1.42 |
| 2016-06-24 | Downgrade | Jyske Bank | Neutral to Sell | |
| 2016-06-07 | Reiterated Rating | Morgan Stanley | Sell | |
| 2016-06-03 | Reiterated Rating | Mizuho | Buy | $84.00 |
| 2016-05-24 | Reiterated Rating | Credit Suisse | Hold | |
| 2016-05-24 | Reiterated Rating | Credit Suisse Group AG | Hold | |
| 2016-05-22 | Reiterated Rating | KeyBanc | Hold | |
| 2016-05-22 | Reiterated Rating | KeyCorp | Hold | |
| 2016-05-16 | Reiterated Rating | Robert W. Baird | Hold | |
| 2016-05-02 | Reiterated Rating | Robert W. Baird | Hold | |
| 2016-04-23 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-04-22 | Boost Price Target | Barclays | Equal Weight | $72.00 to $75.00 |
| 2016-04-22 | Boost Price Target | RBC Capital | Sector Perform | $70.00 to $76.00 |
| 2016-04-22 | Boost Price Target | Barclays PLC | Equal Weight | $72.00 to $75.00 |
| 2016-04-22 | Boost Price Target | Royal Bank Of Canada | Sector Perform | $70.00 to $76.00 |
| 2016-04-21 | Reiterated Rating | Mizuho | Buy | $75.00 to $84.00 |
| 2016-03-23 | Boost Price Target | Goldman Sachs | $71.00 | |
| 2016-03-23 | Boost Price Target | Goldman Sachs Group Inc. | $71.00 | |
| 2016-03-15 | Initiated Coverage | Credit Suisse | Neutral | $72.00 |
| 2016-03-01 | Upgrade | Mizuho | Neutral to Buy | $68.00 to $75.00 |
| 2016-01-29 | Reiterated Rating | William Blair | Hold | |
| 2016-01-29 | Lower Price Target | Barclays | Equal Weight | $74.00 to $72.00 |
| 2016-01-29 | Lower Price Target | RBC Capital | Sector Perform | $73.00 to $70.00 |
| 2016-01-07 | Boost Price Target | Barclays | Equal Weight | $72.00 to $74.00 |
| 2015-11-13 | Boost Price Target | Canaccord Genuity | Buy | $72.00 to $75.00 |
| 2015-10-25 | Reiterated Rating | Canaccord Genuity | Buy | $72.00 |
| 2015-10-23 | Reiterated Rating | William Blair | Hold | |
| 2015-10-23 | Lower Price Target | Goldman Sachs | Neutral | $76.00 to $70.00 |
| 2015-10-23 | Lower Price Target | Barclays | Equal Weight | $78.00 to $72.00 |
| 2015-10-23 | Lower Price Target | RBC Capital | Sector Perform | $77.00 to $70.00 |
| 2015-10-22 | Lower Price Target | Mizuho | Neutral | $76.00 to $68.00 |
| 2015-10-16 | Upgrade | Wells Fargo | Underperform to Market Perform | |
| 2015-10-16 | Upgrade | Wells Fargo & Co. | Underperform to Market Perform | |
| 2015-08-03 | Lower Price Target | Canaccord Genuity | Buy | $85.00 to $82.00 |
| 2015-06-23 | Downgrade | Goldman Sachs | Buy to Neutral | $76.00 |
| 2015-06-16 | Initiated Coverage | KeyBanc | Sector Weight | |
| 2015-06-09 | Reiterated Rating | Jefferies Group | Hold | |
| 2015-06-01 | Reiterated Rating | Mizuho | Buy | $71.00 to $76.00 |
| 2015-05-24 | Reiterated Rating | Canaccord Genuity | Buy | $85.00 |
| 2015-04-23 | Set Price Target | Canaccord Genuity | Buy | $85.00 |
| 2015-04-14 | Boost Price Target | Canaccord Genuity | Buy | $82.00 to $85.00 |
| 2015-03-27 | Initiated Coverage | JMP Securities | Market Perform | |
| 2015-03-25 | Downgrade | Deutsche Bank | Buy to Hold | $77.00 to $80.00 |
| 2015-03-25 | Downgrade | Deutsche Bank AG | Buy to Hold | $77.00 to $80.00 |
| 2015-03-03 | Upgrade | Canaccord Genuity | Hold to Buy | $63.00 to $82.00 |
| 2015-03-02 | Initiated Coverage | Barclays | Equal Weight | $78.00 |
| 2015-02-26 | Downgrade | Goldman Sachs | Conviction-Buy to Buy | |
| 2015-02-23 | Downgrade | Bank of America | Neutral to Underperform | $71.00 to $68.00 |
| 2015-02-23 | Downgrade | Bank of America Corp. | Neutral to Underperform | $71.00 to $68.00 |
| 2015-01-30 | Boost Price Target | Jefferies Group | Hold | $65.00 to $74.00 |
| 2015-01-30 | Boost Price Target | Citigroup Inc. | Neutral | $65.00 to $74.00 |
| 2015-01-30 | Downgrade | Wells Fargo & Co. | Market Perform to Underperform | |
| 2015-01-30 | Boost Price Target | Mizuho | Neutral | $64.00 to $71.00 |
| 2015-01-30 | Downgrade | Wells Fargo | Market Perform to Underperform | |
| 2015-01-29 | Downgrade | Craig Hallum | Buy to Hold | |
| 2015-01-28 | Set Price Target | Morgan Stanley | Sell | $69.00 |
| 2015-01-02 | Upgrade | Raymond James | Underperform to Market Perform | |
| 2015-01-02 | Upgrade | Raymond James Financial Inc. | Underperform to Market Perform | |
| 2014-12-29 | Set Price Target | Bank of America | Hold | $65.00 to $68.00 |
| 2014-12-18 | Reiterated Rating | Goldman Sachs | Buy | $79.00 |
| 2014-11-13 | Upgrade | Deutsche Bank | Hold to Buy | $64 to $75 |
| 2014-09-03 | Upgrade | Goldman Sachs | Buy to Conviction-Buy | $66.00 to $78.00 |
| 2014-07-25 | Boost Price Target | Maxim Group | Buy | $68.00 to $74.00 |
| 2014-07-25 | Reiterated Rating | Citigroup Inc. | Neutral | $60.00 to $65.00 |
| 2014-07-25 | Boost Price Target | Canaccord Genuity | Hold | $55.00 to $58.00 |
| 2014-07-24 | Reiterated Rating | Mizuho | Neutral | |
| 2014-07-03 | Boost Price Target | Mizuho | Neutral | $63.00 to $64.00 |
| 2014-05-08 | Upgrade | Bank of America | Underperform to Neutral | $58.00 |
| 2014-04-14 | Boost Price Target | Credit Suisse | $55.00 to $62.00 | |
| 2014-04-11 | Boost Price Target | Goldman Sachs | $61.00 to $67.00 | |
| 2014-04-02 | Boost Price Target | Mizuho | Neutral | $54.00 to $63.00 |
| 2014-03-19 | Boost Price Target | RBC Capital | $52.00 to $53.00 | |
| 2014-03-10 | Boost Price Target | Goldman Sachs | $61.00 | |
| 2014-03-10 | Initiated Coverage | Piper Jaffray | Neutral | |
| 2014-01-31 | Lower Price Target | SunTrust | $66.00 to $60.00 | |
| 2014-01-31 | Lower Price Target | Deutsche Bank | $62.00 to $59.00 | |
| 2014-01-31 | Lower Price Target | Mizuho | Neutral | $64.00 to $54.00 |
| 2014-01-28 | Initiated Coverage | Maxim Group | Buy | $73.00 to $68.00 |
| 2014-01-27 | Lower Price Target | FBR & Co. | Market Perform | $68.00 to $60.00 |
| 2013-12-18 | Initiated Coverage | JMP Securities | Market Perform | |
| 2013-12-12 | Reiterated Rating | Morgan Stanley | Underweight | $58.00 |
| 2013-12-11 | Reiterated Rating | Citigroup Inc. | Neutral | $59.00 to $58.00 |
| 2013-12-10 | Downgrade | Bank of America | Buy to Underperform | $64.00 to $55.00 |
| 2013-11-19 | Initiated | ISI Group | Neutral | $63 |
| 2013-11-19 | Initiated Coverage | Evercore ISI | Neutral | $63.00 |
| 2013-11-08 | Initiated Coverage | FBR & Co. | Market Perform | $68.00 |
| 2013-10-18 | Lower Price Target | Canaccord Genuity | Hold | $59.00 to $55.00 |
| 2013-10-17 | Lower Price Target | Mizuho | Neutral | $62.00 to $58.00 |
| 2013-10-11 | Reiterated Rating | Citigroup Inc. | Neutral | $64.00 to $60.00 |
| 2013-10-10 | Reiterated Rating | Wells Fargo & Co. | Market Perform | |
| 2013-10-10 | Reiterated Rating | Wells Fargo | Market Perform | |
| 2013-10-02 | Boost Price Target | Goldman Sachs | Buy | $66.00 to $71.00 |
| 2013-09-19 | Initiated Coverage | Craig Hallum | Buy | |
| 2013-07-12 | Initiated | Robert W. Baird | Neutral | $58 |
| 2013-01-29 | Initiated | Oppenheimer | Underperform | $53 |
| 2013-01-24 | Reiterated | Mizuho | Neutral | $63 to $58 |
| 2012-07-02 | Reiterated | Mizuho | Neutral | $61 to $62 |
| 2012-06-21 | Initiated | Canaccord Genuity | Hold | $60 |
| 2011-11-07 | Upgrade | RBC Capital Mkts | Sector Perform to Outperform | $50 to $68 |
| 2011-10-25 | Downgrade | Standpoint Research | Buy to Hold | |
| 2011-10-10 | Downgrade | Maxim Group | Buy to Hold | |
| 2011-08-11 | Upgrade | Standpoint Research | Hold to Buy | $60 |
| 2016-06-24 | Downgrade | Jyske Bank | Neutral to Sell | |
| 2016-06-07 | Reiterated Rating | Morgan Stanley | Sell | |
| 2016-06-03 | Reiterated Rating | Mizuho | Buy | $84.00 |
| 2016-05-24 | Reiterated Rating | Credit Suisse | Hold | |
| 2016-05-24 | Reiterated Rating | Credit Suisse Group AG | Hold |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In DGX 561 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 14.16M |
| BlackRock Inc. | 12.70M |
| STATE STREET CORP | 5.98M |
| BLACKROCK ADVISORS LLC | 4.41M |
| BlackRock Institutional Trust Company, N.A. | 4.37M |
| BlackRock Fund Advisors | 3.25M |
| VICTORY CAPITAL MANAGEMENT INC | 3.22M |
| AMERICAN CENTURY COMPANIES INC | 3.07M |
| BANK OF AMERICA CORP /DE/ | 2.93M |
| GEODE CAPITAL MANAGEMENT, LLC | 2.44M |
| DIMENSIONAL FUND ADVISORS LP | 2.13M |
| BlackRock Group LTD | 1.97M |
| MORGAN STANLEY | 1.95M |
| Invesco Ltd. | 1.95M |
| DAVIS SELECTED ADVISERS | 1.87M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| RUSCKOWSKI STEPHEN H President and CEO | 0.13% (191069) | COV / DGX / XRX / |
| HAGEMANN ROBERT SVP & Chief Financial Officer | 0.09% (126722) | DGX / GPK / R / ZMH / |
| Doherty Catherine T. SVP, Clinical Franchises | 0.05% (67941) | DGX / |
| GUINAN MARK Senior Vice President & CFO | 0.04% (53767) | DGX / HRC / |
| Cunningham Everett SVP, Commercial | 0.03% (45916) | DGX / |
| PREVOZNIK MICHAEL E SVP & General Counsel | 0.03% (39771) | DGX / |
| Davis J. E. SVP, Operations | 0.03% (37067) | DGX / |
| STANZIONE DANIEL | 0.02% (34675) | DGX / INAP / |
| Cohen Jon R SVP and Chief Medical Officer | 0.02% (31757) | DGX / |
| BUEHLER WILLIAM F | 0.02% (26225) | DGX / |
| WILENSKY GAIL R | 0.02% (24960) | DGX / UNH / |
| BRITELL JENNE K | 0.01% (21476) | CCK / DGX / URI / |
| EGLINTON MANNER CARRIE SVP, Advanced Diagnostics | 0.01% (21274) | DGX / |
| Haydon John B. SVP, Operations | 0.01% (19890) | DGX / |
| ZIEGLER JOHN B | 0.01% (16557) | DGX / |
| PFEIFFER GARY M | 0.01% (15534) | DGX / INAP / SZYM / |
| MAIN TIMOTHY L | 0.01% (14691) | DGX / JBL / |
| RING TIMOTHY M | 0.01% (14585) | BCR / BDX / DGX / |
| BALDWIN JOHN C MD | 0.01% (12949) | DGX / |
| BONGIORNO THOMAS F VP and Corporate Controller | 0.01% (11837) | DGX / EVHC / |
| ORDONEZ KATHY SVP, Diagnostic Solutions | 0.01% (9569) | DGX / PACB / |
| Gregg Vicky B | 0.01% (8525) | ACHC / DGX / FHN / TMH / |
UM